general Archived signal Translated · English · 2–5m lag

New disappointment in the search for ALS: Novartis has stopped development of experimental medicinal products

Pharmacetic major Novartis has stopped the development of experimental VHB937 for treatment of amyotrophic lateral sclerosis (ALS), one of the most severe advanced neurological diseases.

Reported by 24ur
Read the complete report at 24ur
Verification notice

IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.

INCIDENT FUSION

2 reports · 2 sources

24urNew disappointment in the search for ALS: Novartis has stopped development of experimental medicinal products24urNew disappointment in the search for ALS: Novartis has stopped development of experimental medicinal products
INCIDENT EVOLUTION

9 recorded states

Signal first indexedP1 · 68% quality · 1 source

Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources

Quality 72→76P1 · 76% quality · 2 sources

Quality 76→80P1 · 80% quality · 2 sources

Quality 80→84P1 · 84% quality · 2 sources

Quality 84→88P1 · 88% quality · 2 sources

Quality 88→92P1 · 92% quality · 2 sources

Quality 92→96P1 · 96% quality · 2 sources

Quality 96→99P1 · 99% quality · 2 sources

Explore this day in the archive →
QUALITY CONTROL

Report this signal

Reports are anonymous and retained privately for editorial review.